The 50th Anniversary of the Discovery of the First Statin by Prof. Dr. Akira Endo: Lipid-Lowering Drugs and Strategies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 357
Special Issue Editors
Interests: lipoproteins; atherosclerosis; coronary heart disease; familial hypercholesterolemia; low-density lipoprotein (LDL) receptor; heart failure; gene therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The rate-controlling enzyme of cholesterol synthesis is 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase). In the midsummer of 1972, Dr. Akira Endo and his team discovered that the mold Penicillium citrinum, which was isolated from a rice sample collected at a grain shop in Kyoto, inhibited HMG-CoA reductase. In July 1973, they isolated three active metabolites from the culture broth and the most active product of these three was named ML-236B, also known as compactin or mevastatin. This discovery led to the development of statins as hypolipidemic drugs, resulting in the demonstration of the efficacy of statins in multiple primary and secondary prevention trials. To celebrate the 50th anniversary of Dr. Akira Endo’s truly unique and historic contribution to science and medicine, this commemorative Special Issue focuses on lipid-lowering drugs and strategies, including biological drug products.
Prof. Dr. Bart De Geest
Dr. Takayuki Masaki
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypolipidemic drugs
- cholesterol
- lipoproteins
- triglycerides
- atherosclerosis
- coronary heart disease
- low-density lipoprotein (LDL) receptor
